Currently Viewing:
Newsroom
Currently Reading
Nivolumab Approved in Patients With Recurrent SCCHN
November 10, 2016 – AJMC Staff
ASCO Upgrades Guidelines to Include Palliative Care in Standard Oncology Care
November 10, 2016 – Surabhi Dangi-Garimella, PhD
How Do Distress Tests Impact Cancer Care Providers?
November 09, 2016 – Surabhi Dangi-Garimella, PhD
Soda Taxes Pass in Four Cities, But Tobacco Votes Are Mixed
November 09, 2016 – Mary Caffrey
New Digital Tool to Compare Insurance Coverage for Cancer Screening Tests
November 08, 2016 – Surabhi Dangi-Garimella, PhD
Meta-Analysis Confirms Clinical Advantage of BRAF/MEK and PD-1 Inhibitors in Melanoma
November 07, 2016 – Surabhi Dangi-Garimella, PhD
Value of Second Opinion in Prostate Cancer Uncertain, Says Hopkins Study
November 07, 2016 – Surabhi Dangi-Garimella, PhD
US Economic Burden Attributable to Adult Vaccine-Preventable Diseases Estimated at $9 Billion
November 06, 2016 – Jackie Syrop
A Diagnostic Tool for Cachexia in Cancer Patients Could Save Lives
November 04, 2016 – Surabhi Dangi-Garimella, PhD

Nivolumab Approved in Patients With Recurrent SCCHN

AJMC Staff
The FDA today granted approval to the programmed death ligand-1 inhibitor, nivolumab (Opdivo), for treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN), following platinum-based treatment.
The FDA today granted approval to the programmed death ligand-1 inhibitor, nivolumab (Opdivo), for treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN), following platinum-based treatment.

The approval followed results from the phase 3 CheckMate-141 trial, in which nivolumab significantly improved overall survival (OS) compared with the comparator drug. The trial enrolled 361 patients who were randomized to receive either nivolumab (3 mg/kg every 2 weeks) or chemotherapy (either cetuximab, 400 mg/m2 once then 250 mg/m2 weekly; methotrexate, 40 mg/m2 weekly; or docetaxel 30 mg/m2 weekly).

The estimated median OS with nivolumab was 7.5 months (95% CI, 5.5-9.1) and 5.1 months for chemotherapy (95% CI, 4-6.0). Serious adverse events were observed in 49% of patients treated with nivolumab, the most frequent being pneumonia, dyspnea, respiratory failure, respiratory tract infection, and sepsis.

“Squamous cell carcinoma of the head and neck that progresses on or after platinum-based therapy is a debilitating and hard-to-treat disease associated with a very poor prognosis,” said Maura Gillison, MD, PhD, lead investigator, Jeg Coughlin Chair of Cancer Research, The Ohio State University Wexner Medical Center, in an associated press release by Bristol-Myers Squibb, the developer of nivolumab. “This latest approval for Opdivo reinforces the potential to provide patients with improved overall survival, considered the gold standard in cancer care.”

Nivolumab has been approved for the treatment of 4 other tumor types. 

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up